[{"orgOrder":0,"company":"RQ Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innovative Antibody Discovered by RQ Bio Enters Clinic as Part of Antibody Combination Within 12 Months of Discovery","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"AZD3152","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"RQ Bio","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"RQ Bio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"RQ Bio \/ Not Applicable"},{"orgOrder":0,"company":"RQ Bio","sponsor":"AbCellera","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AbCellera and RQ Bio Partner to Accelerate the Advancement of New Therapies for Infectious Disease","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Collaboration","leadProduct":"Antibody","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"RQ Bio","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"RQ Bio \/ RQ Bio","highestDevelopmentStatusID":"2","companyTruncated":"RQ Bio \/ RQ Bio"}]

Find Clinical Drug Pipeline Developments & Deals by RQ Bio

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          FNCE 2024
                          Not Confirmed
                          FNCE 2024
                          Not Confirmed

                          Details : The partnership aims to provide long-lasting infectious diseases medicines to high-risk patients by bringing together RQ Bio’s expertise in infectious diseases and viral evolution with AbCellera’s discovery engine for finding rare, highly potent anti...

                          Brand Name : Undisclosed

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          March 22, 2023

                          Lead Product(s) : Antibody

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Discovery

                          Recipient : AbCellera

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          02

                          FNCE 2024
                          Not Confirmed
                          FNCE 2024
                          Not Confirmed

                          Details : AZD5156 is an investigational, long-acting antibody combination of cilgavimab, a component of EVUSHELD (tixagevimab and cilgavimab, formerly AZD7442), and a new long-acting monoclonal antibody (mAb), AZD3152.

                          Brand Name : AZD5156

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          December 21, 2022

                          Lead Product(s) : AZD3152,Cilgavimab

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank